-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) Reports Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients
-
-
-
-
-
-
-
BridgeBio Pharma Inc. (BBIO) prices 8.82 million shares at $17
-
-
-
-
-
-
-
BridgeBio Pharma Inc. (BBIO) Announces Asset Purchase Agreement with Sentynl for BridgeBio Pharma’s NULIBRY (Fosdenopterin)
-
-
-
-
-
-
-
BridgeBio Pharma, Inc. Announces Launch of Secondary Offering of Common Stock
-
-
-
-
-
71,781 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

